Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSavills Regulatory News (SVS)

Share Price Information for Savills (SVS)

Share Price is delayed by 15 minutes
Get Live Data
827.00    5.00 (0.61%)
Bid:
825.00
Ask:
827.00
Spread: 2.00 (0.242%)
Market Cap: £1.15b
SVS Live PriceLast checked at - London Stock Exchange

Intraday Savills Share Chart

Director/PDMR Shareholding

26 May 2022 15:56

RNS Number : 9801M
Savills PLC
26 May 2022
 

SAVILLS PLC (THE "COMPANY")

TRANSACTION IN SHARES BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMRS)

 

Vesting of Share Awards

 

On 26 May 2022, ordinary shares of the Company have been allotted to Directors and PDMRs of the Company as follows in satisfaction of the partial vesting of Awards made on 22 May 2017 under the Performance Share Plan:-

 

Director / PDMR

Number of Shares Transferred

Number of Shares Disposed

Shareholding following this notification

Shareholding as a % of issued share capital

Beneficial interest under the Performance Share Plan following this notification

Mark Ridley (Director)

26,830

26,830

231,854

0.16

242,453

Simon Shaw (Director)

26,830

26,830

182,579

0.13

188,176

Chris Lee (PDMR)

7,985

7,985

119,000

0.08

95,690

 

The share price on disposal of all shares was £10.952661 per share.

 

The balance of the Awards made on 22 May 2017 have lapsed.

 

On 25 May 2022 the grant of an award has been made under The Schedule to The Savills Deferred Share Plan to a PDMR based in the United States of America as follows:-

 

PDMR

Number of shares subject to the Savills Deferred Share Plan awarded to the PDMR on 25 May 2022

Resulting beneficial interest under the Savills Deferred Share Plan

David Lipson

25,847

127,017

 

20% of the above award will vest on 18 April 2023, being the anniversary of the programme's original inception, and then 20% on each of the subsequent four anniversaries of that date subject to continued employment and satisfaction of performance criteria relating to gross billings.

 

The award is subject to rolled-up dividend shares whereby the number of shares awarded shall be increased on the vesting dates to reflect final and interim dividends declared during the Deferred Periods.

 

 

The information set out below is provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation No 596/2014.

1.

Details of the Director/ PDMR

 

(a)

Name

1. Mark Ridley

2. Simon Shaw

3. Chris Lee

4. David Lipson

 

2.

Reason for the notification

 

(a)

Position/ status

1. Group Chief Executive/ Director

2. Group Chief Financial Officer/ Director

3. Group Legal Director and Company Secretary/ PDMR

4. President - Savills North America/ PDMR

 

(b)

Initial notification/ Amendment

 

Initial notification

3.

Details of the issuer

 

(a)

Name

Savills plc

 

(b)

LEI

213800WXICGMBWHTA933

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

(a)

Description of the Financial Instrument

 

Savills plc Ordinary Shares of 2.5p each

(b)

Identification code of the Financial Instrument

 

GB00B135BJ46

(c)

Nature of the transaction

 

Vesting of awards under the Company's Performance Share Plan and sale of resultant shares for persons 1 - 3

 

(d)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

Acquisition

£0.025 per share

 

1. 26,830

2. 26,830

3. 7,985

 

Disposal

£10.952661 per share

1. 26,830

2. 26,830

3. 7,985

 

(e)

Aggregated information

 

- Aggregated volume

- Price

 

N/A

 

 

(f)

Date of the transaction

 

26 May 2022

(g)

Place of the transaction

 

London Stock Exchange (XLON)

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

(a)

Description of the Financial Instrument

Award over Savills plc Ordinary Shares in accordance with the Company's Deferred Share Plan

 

(b)

Identification code of the Financial instrument

GB00B135BJ46

(c)

Nature of the transaction

Grant of an award over Ordinary Shares in accordance with the Company's Deferred Share Plan in respect of David Lipson

 

(d)

Price(s) and volume(s)

Price(s)

Volume(s)

£nil per share

25,847

(d)

Aggregated information

 

- Aggregated volume

- Price

N/A

(f)

Date of the transaction

25 May 2022

(g)

Place of the transaction

Outside a trading venue

 

Name of contact and telephone number for queries:

Chris Lee

Group Legal Director & Company Secretary

020 3107 5444

 

26 May 2022

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKZGZKDVKGZZM
Date   Source Headline
1st Jun 202611:29 amRNSTotal Voting Rights
22nd May 202610:09 amRNSDirector/PDMR Shareholding
14th May 202612:41 pmRNSResult of AGM
13th May 20264:16 pmRNSResult of AGM
13th May 20267:00 amRNSAGM Statement
12th May 20263:41 pmRNSDirector/PDMR Shareholding
7th May 20263:39 pmRNSDirector Declaration
29th Apr 20263:04 pmRNSReplacement - Director/PDMR Shareholding
29th Apr 20261:23 pmRNSDirector/PDMR Shareholding
28th Apr 20261:58 pmRNSDirector/PDMR Shareholding
13th Apr 20265:24 pmRNSHolding(s) in Company
13th Apr 20262:10 pmRNSDirector/PDMR Shareholding
7th Apr 20264:03 pmRNSAnnual Report and AGM Notice
1st Apr 202610:00 amRNSTotal Voting Rights
31st Mar 202612:55 pmRNSDirector/PDMR Shareholding
26th Mar 20268:57 amRNSDirector/PDMR Shareholding
24th Mar 202611:02 amRNSDirector/PDMR Shareholding
23rd Mar 20269:27 amRNSDirector/PDMR Shareholding
18th Mar 20263:47 pmRNSDirector/PDMR Shareholding
16th Mar 20262:33 pmRNSHolding(s) in Company
16th Mar 20262:33 pmRNSHolding(s) in Company
16th Mar 20262:00 pmRNSHolding(s) in Company
16th Mar 20262:00 pmRNSHolding(s) in Company
16th Mar 202611:51 amRNSDirector/PDMR Shareholding
16th Mar 202611:51 amRNSDirector/PDMR Shareholding
16th Mar 202611:49 amRNSDirector/PDMR Shareholding
16th Mar 202611:49 amRNSDirector/PDMR Shareholding
13th Mar 20261:34 pmRNSDirector/PDMR Shareholding
13th Mar 20261:32 pmRNSDirector/PDMR Shareholding
12th Mar 20267:26 amRNSSignificant Transaction
12th Mar 20267:26 amRNSSignificant Transaction
12th Mar 20267:08 amRNSFinal Results
11th Mar 20264:21 pmRNSDirector/PDMR Shareholding
11th Mar 20264:21 pmRNSDirector/PDMR Shareholding
5th Mar 20265:00 pmRNSHolding(s) in Company
2nd Mar 20269:11 amRNSTotal Voting Rights
25th Feb 202611:14 amRNSHolding(s) in Company
11th Feb 20264:07 pmRNSDirector/PDMR Shareholding
4th Feb 20265:29 pmRNSHolding(s) in Company
2nd Feb 20265:32 pmRNSTotal Voting Rights
19th Jan 20268:30 amRNSDirectorship change
15th Jan 20267:00 amRNSYear End Trading Update
13th Jan 20265:40 pmRNSDirector/PDMR Shareholding
13th Jan 202612:59 pmRNSHolding(s) in Company
2nd Jan 20263:00 pmRNSTotal Voting Rights
11th Dec 20252:00 pmRNSDirector/PDMR Shareholding
1st Dec 20259:49 amRNSTotal Voting Rights
11th Nov 20254:58 pmRNSDirector/PDMR Shareholding
3rd Nov 202512:32 pmRNSTotal Voting Rights
13th Oct 20251:33 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.